نتایج جستجو برای: ursodeoxycholic acid udca

تعداد نتایج: 747520  

Journal: :Minerva gastroenterologica e dietologica 2000
A Parés J Rodés

Primary biliary cirrhosis is a chronic liver disease of unknown etiology, characterized by inflammation and destruction of the intrahepatic biliary ducts, resulting in chronic cholestasis and eventually cirrhosis. The main clinical manifestations consists of pruritus, jaundice, xanthomas, and the consequences of intestinal malabsorption, including vitamin deficiencies and osteodystrophy. Treatm...

2014
Rui-rui Chen Yuan-jun Li Xin-min Zhou Lu Wang Juan Xing Shuang Han Li-na Cui Lin-hua Zheng Kai-chun Wu Yong-quan Shi Zhe-yi Han Ying Han Dai-ming Fan

BACKGROUND Primary biliary cirrhosis (PBC) is a chronic and progressive cholestasis liver disease. Bile salt export pump (BSEP) is the predominant bile salt efflux system of hepatocytes. BSEP gene has been attached great importance in the susceptibility of PBC and the response rate of ursodeoxycholic acid (UDCA) treatment of PBC patients. METHODS In this study, TaqMan assay was used to genoty...

2014
Malgorzata Milkiewicz Justyna Kopycińska Agnieszka Kempińska-Podhorodecka Tara Haas Dimitrios P. Bogdanos Elwyn Elias Piotr Milkiewicz

BACKGROUND Enhanced expression of cell cycle inhibitor p27(kip1) suppresses cell proliferation. Ursodeoxycholic acid (UDCA) delays progression of primary biliary cirrhosis (PBC) but its effect on p27(kip1) expression is uncertain. AIMS To analyze the expression of p27(kip1) and its transcription modulator FoxO1 in patients with PBC, and to assess the impact of UDCA on this pathway. MATERIAL...

2012
Anika Tschirner Jochen Springer

Dear Editor, In a recent letter [1], Dr. Kapoor commented on our paper describing the effects of ursodeoxycholic acid (UDCA) in a model of severe cancer cachexia [2]. Dr. Kapoor is obviously correct in stating that there is emerging data showing that bile acids such as UDCA may be beneficial in gastrointestinal cancers by attenuating cancer progression. However, in our study, the aim was to cha...

Journal: :Blood 2002
Tapani Ruutu Britta Eriksson Kari Remes Eeva Juvonen Liisa Volin Mats Remberger Terttu Parkkali Hans Hägglund Olle Ringdén

The role of ursodeoxycholic acid (UDCA) in the prevention of hepatic complications after allogeneic stem cell transplantation was studied in a prospective randomized open-label multicenter trial. A total of 242 patients were allocated to receive (n = 123) or not to receive (n = 119) UDCA in the dose of 12 mg/kg/d orally from the day preceding the conditioning until day 90 after transplantation....

2017
Yuichi Torisu Masanori Nakano Keiko Takano Ryo Nakagawa Chisato Saeki Atsushi Hokari Tomohisa Ishikawa Masayuki Saruta Mikio Zeniya

AIM To evaluate the therapeutic effects of ursodeoxycholic acid (UDCA) on autoimmune hepatitis (AIH). METHODS A total 136 patients who were diagnosed with AIH were included in our study. All of the patients underwent a liver biopsy, and had at least a probable diagnosis on the basis of either the revised scoring system or the simplified scores. Initial treatment included UDCA monotherapy (Gro...

2009
Keith D. Lindor Kris V. Kowdley Velimir A. C. Luketic M. Edwyn Harrison Timothy McCashland Alex S. Befeler Denise Harnois Roberta Jorgensen Jan Petz Jill Keach Jody Mooney Carol Sargeant Tamara Bernard Debra King Ellen Miceli Jeff Schmoll Tanya Hoskin Prabin Thapa Felicity Enders

Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long-term, randomized, double-blind controlled trial of highdose UDCA (28-30 mg/kg/day) versus placebo. Liver biopsy and cholangiography were performed before randomization and after 5 ye...

Journal: :Terapevticheskii arkhiv 2014
S Iu Martsevish N P Kutishenko L Iu Drozdova O V Lerman V A Nevzorova I I Reznik G V Shavkuta D A Iakhontov RACURS study group

AIM To evaluate the efficiency and safety of using statins in combination with ursodeoxycholic acid (UDCA) in patients with this or another liver disease at high risk for cardiovascular events (CVE). SUBJECTS AND METHODS A register of 262 patients at high risk for CCE who needed statin therapy and have concomitant chronic liver and biliary tract diseases was created in 5 cities of the Russian...

Journal: :Gut 1994
M Boscaini M Piccinni-Leopardi F Andreotti A Montori

Between November 1988 and July 1992 70 patients with radiolucent gall stones were treated with extracorporeal lithotripsy (ESL) and ursodeoxycholic acid (UDCA; mean (SD) dose 11.2 (1.9) mg/kg/day). Fifty three patients have been followed for one year. One week after lithotripsy, 30.6% had completely eliminated all stone fragments from the gall bladder and one year later 93.9% were free of stone...

Journal: :Organic & biomolecular chemistry 2012
Francesco Venturoni Antimo Gioiello Roccaldo Sardella Benedetto Natalini Roberto Pellicciari

A multi-gram scale protocol for the N-acyl amidation of bile acids with glycine and taurine has been successfully developed under continuous flow processing conditions. Selecting ursodeoxycholic acid (UDCA) as the model compound and N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) as the condensing agent, a modular mesoreactor assisted flow set-up was employed to significantly speed up the...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید